FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020

Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020

CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been nationally recognized as a Great Place to Work-Certified Company in 2020. Great Place to Work® is the global authority on workplace culture, employee experience and leadership behaviors proven to deliver market-leading revenue and increased innovation. This Certification utilizes validated employee feedback based on the Great Place to Work’s data driven methodology and indicates that Amicus employees consistently acknowledge a positive work experience and value the overall corporate culture of the company.

“We are very pleased to receive the Great Place to Work Certification, as this recognition comes as a result of extraordinary efforts to design and deploy programs that enhance the Amicus employee experience,” stated David Clark, Chief People Officer of Amicus Therapeutics, Inc. “The certification process reflected many of our core strengths including the sense of purpose around our mission and our commitment to respecting our diverse backgrounds. At Amicus, we take pride in the talented individuals that make up our organization and work hard to foster their growth. We actively engage with our employees to ensure we are harnessing their capabilities and expertise so that we can provide a corporate culture that drives performance and ultimately attracts, energizes and retains the right talent. We are united by our commitment to building a highly engaged and inclusive corporate culture, driven by our Mission-Focused Behaviors, as we strive to be champions of the rare disease community.”

Sarah Lewis-Kulin, Vice President of Best Workplace List Research at Great Place to Work, stated, “We congratulate Amicus Therapeutics on their Certification. Organizations that earn their employees’ trust create great workplace cultures that deliver outstanding business results.”

About Great Place® to Work

Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust. Great Place to Work helps organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees. Everything they do is driven by the mission to build a better world by helping every organization become a Great Place to Work For All™.

To learn more, visit , listen to the podcast , and read  Join the community on ,  and .

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at , and follow us on and .

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Director, Investor Relations 

(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Communications

(609) 662-5079

FOLD–G



EN
07/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE

Amicus Therapeutics Announces Second Quarter 2025 Financial Results an...

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, tod...

 PRESS RELEASE

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results ...

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event...

 PRESS RELEASE

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase ...

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). "We are delighted that we will now be able to offer a compel...

 PRESS RELEASE

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (mig...

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. ...

 PRESS RELEASE

Amicus Therapeutics to Present at Upcoming Investor Conferences in Jun...

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ETGoldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors sectio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch